Crespo-Bravo, Marina
Thorlacius-Ussing, Jeppe
Nissen, Neel I.
Pedersen, Rasmus S.
Boisen, Mogens K.
Liljefors, Maria
Johansen, Astrid Z.
Johansen, Julia S.
Karsdal, Morten A.
Willumsen, Nicholas
Funding for this research was provided by:
Danish Research Foundation
Article History
Received: 22 June 2023
Accepted: 2 October 2023
First Online: 6 October 2023
Declarations
:
: A patent has been filed for the PRO-C17 ELISA. J.T.-U., N.I.N., M.A.K. and N.W. are employed at Nordic Bioscience A/S, a biotech company involved in the discovery and development of blood-based biomarkers. M.C.B., M.K.B., J.S.J., M.L., A.Z.J. and R.A.P. have no conflict of interest to declare. M.A.K. and N.W. own stock in Nordic Bioscience A/S.
: Monoclonal antibody production performed in mice was approved by the Danish National Authority (The Animal Experiments Inspectorate) under approval No. 2018-15-0201-01574. All animals were treated according to the guidelines for animal welfare. The study was conducted in accordance with the ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) to ensure comprehensive and transparent reporting of the methods used in the experiments.
: In cohort 1, serum samples were collected after patients gave their informed consent, approved by the Russian Oncological Research Centre n.a. Blokhin RAMS (PG-ONC 2033/1) (Moscow, Russia) and the Western Institutional Review Board, Inc. (Puyallup, WA, USA) (WIRB®Protocol #20161665). All investigations were conducted in accordance with the Helsinki Declaration.
: In cohort 2, the study was performed according to the recommendations of the Danish Regional Committee on Health Research Ethics. The CREBB protocol was approved by the Danish Regional Committee on Health Research Ethics (Approval ID: H-3-2010-121) and the Data Protection Agency (Approval ID: 2007-58-0015/HEH.750.24-44). The study was conducted in accordance with the principles of the Declaration of Helsinki and all patients provided written informed consent prior to enrolment.
: Not applicable.